Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2017-09-17 | recombinant human monoclonal IgG1 antibody against programmed death ligand-1 (anti-PD-L1) | EMD Serono - Merck KGaA (Germany) Pfizer (USA - NY) | Merkel cell carcinoma | Granting of a Market Authorisation in the EU |
2015-10-06 | nanoparticulate paclitaxel | NanOlogy (USA – CA) | ovarian cancer |
Granting of the orphan status in the US |
2015-09-08 | nimotuzumab | InnoCIMab (Singapore) | pancreatic cancer |
Granting of the orphan status in the US |
2015-10-07 | recombinant fusion protein comprising exenatide and XTEN | NAIA Pharmaceuticals (USA – CA) | short bowel syndrome |
Granting of the orphan status in the US |
2015-10-28 | nano-diamino-tetraiodothyroacetic acid | NanoPharmaceuticals (USA – NY) | pancreatic cancer |
Granting of the orphan status in the US |
2015-10-29 | recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP | Voisin Consulting (France)/Agilis Biotherapeutics (USA – MA) | Angelman syndrome |
Granting of the orphan status in the US |
2015-10-29 | monoclonal antibody targeting eotaxin-2 | ChemomAb (Israel) | idiopathic pulmonary fibrosis |
Granting of the orphan status in the US |
2015-09-21 | milciclib maleate | Spark Therapeutics (USA – PA) | hemophilia B |
Granting of the orphan status in the US |
2015-10-09 | mesencephalic, astrocyte-derived neurotrophic factor | Amarantus BioScience (USA – CA) | retinal artery occlusion |
Granting of the orphan status in the US |
2015-09-21 | mecasermin - recombinant human insulin-like growth factor-1 | Keck Graduate Institute of Applied Life Sciences (USA – CA) | Rett Syndrome |
Granting of the orphan status in the US |
2016-06-01 | cross-linked sodium hyaluronate combined with triamcinolone hexacetonide | Anika Therapeutics (USA – MA) | symptomatic relief of osteoarthritis (OA) of the knee |
Product launch |
2015-10-09 | diagnostic test | Dako (Denmark), an Agilent Technologies company (USA - CA) | non small cell lung cancer (NSCLC) |
Granting of a Market Authorisation in the US |
2015-10-02 | companion diagnostic assay | Dako (Denmark), an Agilent Technologies company (USA - CA) | Granting of a Market Authorisation in the US | |
2015-10-02 | companion diagnostic assay for use with Keytruda® (pembrolizumab) | Dako (Denmark), an Agilent Technologies company (USA - CA) | non-small cell lung cancer (NSCLC) | Granting of a Market Authorisation in the US |
2017-12-14 | tofacitinib | Pfizer (USA - NY) | moderate to severe chronic plaque psoriasis | Granting of a Market Authorisation in the US |
2015-11-11 | pentetrazol | Balance Therapeutics (USA – CA)/Dr Jens Steinbrink (Germay) | idiopathic hypersomnia |
Granting of the orphan status in the EU |
2015-09-21 | marizomib | Triphase Research & Development (USA – CA) | malignant glioma |
Granting of the orphan status in the US |
2015-10-29 | lucerastat | Actelion Pharmaceuticals (Switzerland) | Fabry Disease |
Granting of the orphan status in the US |
2015-11-04 | lisinopril oral solution | Silvergate Pharmaceuticals (USA – CO) | hypertension in pediatric patients 0 through 16 years of age |
Granting of a patent |
2015-09-14 | small molecule FGFR4 inhibitor | Blueprint Medicines Corporation (USA – MA) | hepatocellular cancer |
Granting of the orphan status in the US |
© 2024 Biopharmanalyses - Powered by Samacom+